P-163: Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS

Weijun Fu, Honghui Huang, Wei Li, Gang An, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Ming Qi, Jianping Wang, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Yunan Li, Renyi Zhang, Jian Hou, Jianxiang WangClinical 2021 · DOI

BibTeX
@inproceedings{fu2021p,
  author = {Weijun Fu and Honghui Huang and Wei Li and Gang An and Zhen Cai and Jie Jin and Yafei Wang and Chor Sang Chim and Ming Qi and Jianping Wang and Yang Song and Bin Jia and Xue Yang and Wenyu Liu and Yunan Li and Renyi Zhang and Jian Hou and Jianxiang Wang},
  title = {{P-163: Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS}},
  booktitle = {Clinical},
  year = {2021},
  doi = {10.1016/s2152-2650(21)02290-4},
}

Loading related content...

Figure